Tau as a biomarker of neurodegenerative diseases
- 1 August 2008
- journal article
- review article
- Published by Future Medicine Ltd in Biomarkers in Medicine
- Vol. 2 (4), 363-384
- https://doi.org/10.2217/17520363.2.4.363
Abstract
The microtubule-associated protein Tau is mainly expressed in neurons of the CNS and is crucial in axonal maintenance and axonal transport. The rationale for Tau as a biomarker of neurodegenerative diseases is that it is a major component of abnormal intraneuronal aggregates observed in numerous tauopathies, including Alzheimer’s disease. The molecular diversity of Tau is very useful when analyzing it in the brain or in the peripheral fluids. Immunohistochemical and biochemical characterization of Tau aggregates in the brain allows the postmortem classification and differential diagnosis of tauopathies. As peripheral biomarkers of Alzheimer’s disease in the cerebrospinal fluid, Tau proteins are now validated for diagnosis and predictive purposes. For the future, the detailed characterization of Tau in the brain and in peripheral fluids will lead to novel promising biomarkers for differential diagnosis of dementia and monitoring of therapeutics.Keywords
This publication has 167 references indexed in Scilit:
- Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta depositionProceedings of the National Academy of Sciences of the United States of America, 2008
- Refining Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17Archives of Neurology, 2008
- Interaction of tau protein with the dynactin complexThe EMBO Journal, 2007
- Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's diseaseAnnals of Neurology, 2007
- Functional MAPT haplotypes: Bridging the gap between genotype and neuropathologyNeurobiology of Disease, 2007
- Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar DegenerationActa Neuropathologica, 2007
- Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosisZeitschrift für Neurologie, 2007
- HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin‐positive, tau‐negative inclusions caused by a missense mutation in the signal peptide of progranulinAnnals of Neurology, 2006
- Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal deathNature, 2004
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001